TY  - JOUR
AU  - Röhrich, Manuel
AU  - Syed, Mustafa
AU  - Liew, Dawn P
AU  - Giesel, Frederik L
AU  - Liermann, Jakob
AU  - Choyke, Peter L
AU  - Wefers, Annika K
AU  - Ritz, Thomas
AU  - Szymbara, Marina
AU  - Schillings, Lisa
AU  - Heger, Ulrike
AU  - Rathke, Hendrik
AU  - Kratochwil, Clemens
AU  - Huber, Peter E
AU  - von Deimling, Andreas
AU  - Debus, Jürgen
AU  - Kauczor, Hans-Ulrich
AU  - Haberkorn, Uwe
AU  - Adeberg, Sebastian
TI  - 68Ga-FAPI-PET/CT improves diagnostic staging and radiotherapy planning of Adenoid Cystic Carcinomas - imaging analysis and histological validation.
JO  - Radiotherapy and oncology
VL  - 160
SN  - 0167-8140
CY  - Amsterdam [u.a.]
PB  - Elsevier Science
M1  - DKFZ-2021-01009
SP  - 192-201
PY  - 2021
N1  - 2021 May 1;160:192-201
AB  - Adenoid cystic carcinomas (ACCs) are rare epithelial tumors mostly situated in the head and neck region and characterized by infiltrative growth. The tumor stroma of ACCs includes cancer-associated fibroblasts (CAFs) expressing Fibroblast Activation Protein (FAP), a new target for positron emission tomography (PET) imaging. Here we describe the value of PET/ computed tomography (PET/CT) imaging using 68Ga-labelled FAP-Inhibitors (68Ga-FAPI-PET/CT) and their clinical potential for staging and radiotherapy planning in 12 ACC patients (7 primary, 5 recurrent).Patients underwent contrast enhanced staging CT (ceCT) and magnetic resonance imaging (ceMRI) before 68Ga-FAPI - PET/CT. PET-scans were acquired 10, 60 and 180 minutes after administration of 150-250 MBq of 68Ga-labelled FAPI tracers. SUVmax and SUVmean values of ACCs and healthy organs were obtained using a 60
KW  - ACC (Other)
KW  - Adenoid cystic carcinoma (Other)
KW  - FAP (Other)
KW  - Fibroblast Activation Protein (Other)
KW  - Positron Emission Tomography (Other)
KW  - Radiotherapy (Other)
KW  - Staging (Other)
KW  - TNM (Other)
KW  - alpha SMA (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:33940087
DO  - DOI:10.1016/j.radonc.2021.04.016
UR  - https://inrepo02.dkfz.de/record/168701
ER  -